바이오스펙테이터

바이오스펙테이터 Euna Lee 기자

“We are now focusing on the role of cytokine interleukin-7 (IL-7) to enhance the number and function of T cells,” said Yang Se-whan, CEO and president of NeoImmuneTech, Inc. (NIT).

“To address the poor structural stability and low productivity of recombinant IL-7 product, Hyleukin is designed as an immuno-oncology agent to reconstitute and enhance anti-tumoral activity of T cells. Hyleukin consists of optimally engineered homodimeric IL-7 molecules biologically fused with Genexine’s proprietary platform hyFc™ derived from human IgD and IgG1. With stronger T cell boosting and long-acting effects, HyLeukin is expected to exhibit better anti-tumor activity when it is combined with conventional treatment,” CEO Yang elaborated.

CEO Yang introduced Hyleukin as the company’s lead product in an event titled “Biodrug Pipeline Investment Forum” in Yeoido, Seoul on November 13, 2017. The forum was co-organized by Korea Biotechnology Industry Organization and Mirae Asset Daewoo.

Founded in NIT in 2014, NIT was spun off from Genexine, a leading Korean biotech company. Yang was a co-founder of Genexine. He served as the head of R&D center and senior director of development unit. Based in Rockville, Maryland, NIT is expanding its overseas networks.